SARS-CoV-2 viral dynamics in non-human primates

Archive ouverte

Gonçalves, Antonio | Maisonnasse, Pauline | Donati, Flora | Albert, Mélanie | Behillil, Sylvie | Contreras, Vanessa | Naninck, Thibaut | Marlin, Romain | Solas, Caroline | Pizzorno, Andres | Lemaitre, Julien | Kahlaoui, Nidhal | Terrier, Olivier | Ho Tsong Fang, Raphael | Enouf, Vincent | Dereuddre-Bosquet, Nathalie | Brisebarre, Angela | Touret, Franck | Chapon, Catherine | Hoen, Bruno | Lina, Bruno | Rosa Calatrava, Manuel | de Lamballerie, Xavier | Mentré, France | Le Grand, Roger | van Der Werf, Sylvie | Guedj, Jérémie

Edité par CCSD ; PLOS -

International audience. Non-human primates infected with SARS-CoV-2 exhibit mild clinical signs. Here we used a mathematical model to characterize in detail the viral dynamics in 31 cynomolgus macaques for which nasopharyngeal and tracheal viral load were frequently assessed. We identified that infected cells had a large burst size (>10 4 virus) and a within-host reproductive basic number of approximately 6 and 4 in nasopharyngeal and tracheal compartment, respectively. After peak viral load, infected cells were rapidly lost with a half-life of 9 hours, with no significant association between cytokine elevation and clearance, leading to a median time to viral clearance of 10 days, consistent with observations in mild human infections. Given these parameter estimates, we predict that a prophylactic treatment blocking 90% of viral production or viral infection could prevent viral growth. In conclusion, our results provide estimates of SARS-CoV-2 viral kinetic parameters in an experimental model of mild infection and they provide means to assess the efficacy of future antiviral treatments.

Suggestions

Du même auteur

Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates

Archive ouverte | Maisonnasse, Pauline | CCSD

International audience. Coronavirus disease 2019 (COVID-19) has rapidly become a global pandemic and no antiviral drug or vaccine is yet available for the treatment of this disease1-3. Several clinical studies are o...

Antiviral efficacy of favipiravir against Zika and SARS-CoV-2 viruses in non-human primates

Archive ouverte | Marlin, Romain | CCSD

International audience. Abstract The COVID-19 pandemic has exemplified that rigorous evaluation in large animal models is key for translation from promising in vitro results to successful clinical implementation. Am...

COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models

Archive ouverte | Maisonnasse, Pauline | CCSD

International audience. Abstract Effective treatments against Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) are urgently needed. Monoclonal antibodies have shown promising results in patients. Here, w...

Chargement des enrichissements...